Cheryl Ramsden

• Lead marketer for KOL relationships and coordination and execution of Speaker Bureau and Advisory Boards
• Developed all requisite speaker decks for KOL Speaker Bureau and Clinical Nurse Educators, including speaker training
• Identified, directed and managed all aspects of National Patient Advocacy Programs, Patient Ambassadors and Mentor Program
• Assisted senior leadership in managing all aspects of department relevant marketing domains, analytics and budgets

• Provided leadership guidance and oversight of 10 Clinical Nurse Educators throughout Western United States
• Identified key oncology accounts in Western U.S. along with strategic imperatives for developing relationships and providing evidence-based educational programs regarding HER2+ Breast Cancer and role of neratinib in reducing risk of recurrence
• Managed all aspects of CNE West professional development, budgets, and business analytics for reporting to senior management and National Director of CNEs

• Develop and execute robust regional educational business plans for key target accounts within Pacific Northwest to initiate and expand use of neratinib in appropriate patients with HER2+ early-stage breast cancer
• Delivered educational programs to key customers and accounts including, HCPs across academic institutions, community practices and hospital settings involved in treatment and care of breast cancer patients
• Developed and maintain long-term relationships with key stakeholders in breast cancer therapy
• Collaborated with all relevant cross functional commercial and medical affairs partners
• Engaged with commercial team to assist in internal training workshops and development of training materials
• Awards:
• February 2018: Puma Pride Leadership Award
• July 2018: Puma Pride Leadership Award
• July 2019: Puma Roar Leadership Award

• Provided biotechnology and pharmaceutical marketing executives strategic planning and program development and oversight related to brand planning and medical communication/education (promotional and non-promotional)
• Interfaced with clients' agency partners to ensure flawless execution of brand/medical communications strategies and tactics
• Facilitated all aspects of internal and external review processes (KOLs, medical, regulatory and compliance)

• Provided strategic planning, scientific affairs and account development oversight. Primary focus: West Coast biotechnology and pharmaceutical industry
• Advised clients on strategic and tactical KOL advocacy development and planning
• Assisted clients with yearly brand/medical communication/education strategy and tactic business planning
• Developed solutions to improve project management knowledge and efficiency through team development and teaching on numerous disease states
• Disease states included: Rare Diseases, Narcolepsy, Pulmonary Arterial Hypertension, Acute Lymphoblastic Leukemia

• Directed client strategy and scientific affairs (CME and Non-CME) for West Coast biotechnology and pharmaceutical industry accounts
• Guided Project Management teams on CME/Non-CME program development to ensure all educational strategies and scientific messaging were achieved
• Disease States included: Cardiology, Pulmonology, Oncology, Ophthalmology, Dermatology

• Provided medical communication and sales training consulting and program development services to biotech and pharmaceutical industries
• Designed and developed medical communications and sales training products/programs for a variety of biotech and pharmaceutical clients
• Directed and managed multiple scientific, editorial, creative and production teams in all aspects of product/program development
• Managed all aspects of proposal development, budgets and reconciliations and company financials

• Spearheaded the design and development of all sales training materials for the launch of Recombinant Tissue Plasminogen Activator (Activase) for the treatment of Acute Myocardial Infarction
• Coordinated and trained 100 sales representatives in preparation for the launch of Activase
• Trained an additional 200 sales representatives on disease state pathophysiology, diagnosis and management: cardiopulmonary disease, endocrine and immune disease/disorders
• Directed multiple agency partners on the design and development of sales training programs
• Authored several publications on the topics of Acute Myocardial Infarction and Fibrinolysis

Publications:

• Ramsden CS , Treatment strategies following thrombolysis. Heart and Lung, Volume 17, Number 6, November 1988.
• Ramsden CS , Management of the Acute Myocardial Infarction Patient Receiving Fibrinolytic Therapy with Activase, a Tissue Plasminogen Activator, Monograph. Genentech, Inc., 1988.
• Erickson D, Keene E, Kleven M, Ramsden C . A Standardized Nursing Care Plan for the Acute Myocardial Infarction Patient Receiving Activase: A Tissue Plasminogen Activator. Expert to Expert, Volume 1, Number 2, January 1988.
• Topol E, Morris C, Smalling R, et al. A Multi-center, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (Activase) in acute myocardial infarction. JACC, Volume 9, Number 6, June 1987.
• Parr K, Valentine R, Pitts D, Schumacher R, Schmidt P, Brooks-Brunn J, Ramsden C . Recombinant Tissue Plasminogen Activator as a Thrombolytic Agent in Acute Myocardial Infarction. Indiana Medicine, Volume 8, Number 5, May 1987.

Clinical Trials Coordinated:

• A Prospective, Randomized Placebo-controlled Double-Blind Trial of Recombinant Tissue-type Plasminogen Activator Produced in Suspension Culture: Coronary Thrombolysis in Acute Myocardial Infarction. A Multi-center Clinical Trial.
• An Open-label Randomized Trial of Two Doses of Recombinant Human Tissue-type Plasminogen Activator in Acute Myocardial Infarction. A Multi-center Clinical Trial.
• A Double-blind Clinical Trial Evaluating the Safety and Efficacy of Lidoflazine in Ameliorating Post-ischemia Brain Damage after Cardiac Arrest. Clinical Trial Supported by the NIH.
• A Comparison between Cardiac Output Measurements Using Thermodilution vs. Impedence Cardiography. Methodist Hospital of Indiana, Inc., Critical Care Units.
• Neutrophil Function as an Indicator of Severity of Disease in Trauma Patients. Methodist Hospital of Indiana, Inc., Critical Care Units.
• A Multi-center Double Blind Study to Compare the Efficacy and Safety of Once-a-Day Orally Administered Bevantolol with a Twice-a-Day Orally Administered Bevantolol Dosing Regimen in Patients with Classical Effort-induced Angina Pectoris.